Verrica Pharmaceuticals has granted Medomie Pharma exclusive rights to seek regulatory approval and distribute YCANTH in Israel. Verrica will receive 60% of the net selling price and up to $8.2 million in regulatory and commercial milestones, indicating a new market expansion for their product.
Verrica Pharmaceuticals has entered into an agreement with Medomie Pharma, granting them exclusive rights to obtain marketing authorization and distribute YCANTH in Israel. This deal represents a new market expansion for Verrica's product, YCANTH, which is used for the treatment of molluscum contagiosum. Verrica will benefit from a 60% share of the net selling price and is eligible for up to $8.2 million in milestone payments, providing a new revenue stream. While the immediate financial impact might be moderate given the size of the Israeli market, it signifies Verrica's strategy to expand its global reach and monetize its approved therapies. For traders, this presents a long-term opportunity for VRCA as it diversifies its revenue base, though the short-term stock movement may be limited unless the milestone payments are achieved rapidly.